Evidence map›Paper›PMID 35200463›Full record

ReviewGels (Basel, Switzerland)2022

Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System.

Md Habban Akhter, Irfan Ahmad, Mohammad Y Alshahrani, Alhanouf I Al-Harbi, Habibullah Khalilullah, Obaid Afzal, Abdulmalik S A Altamimi, Shehla Nasar Mir Najib Ullah, Abhijeet Ojha, Shahid Karim

Open access · goldAbstract readReview
In one paragraph

Review in Gels (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 166 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Md Habban AkhterSchool of Pharmaceutical and Population Health Informatics (SoPPHI), DIT University, Dehradun 248009, India.
Irfan AhmadDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha 62521, Saudi Arabia.ORCID 0000-0002-9500-4623
Mohammad Y AlshahraniDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha 62521, Saudi Arabia.ORCID 0000-0002-7096-0221
Alhanouf I Al-HarbiDepartment of Medical Laboratory, College of Applied Medical Sciences, Taibah University, Yanbu 46477, Saudi Arabia.ORCID 0000-0003-0889-2886
Habibullah KhalilullahDepartment of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Unaizah 51911, Saudi Arabia.ORCID 0000-0002-7401-6254
Obaid AfzalDepartment of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.ORCID 0000-0002-4188-5592
Abdulmalik S A AltamimiDepartment of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
Shehla Nasar Mir Najib UllahDepartment of Pharmacognosy, Faculty of Pharmacy King Khalid University, Abha 62521, Saudi Arabia.
Abhijeet OjhaSix Sigma Institute of Technology and Science, College of Pharmacy, Rudrapur 263153, India.
Shahid KarimDepartment of Pharmacology, College of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0001-8305-4394
King Khalid University · SAPrince Sattam Bin Abdulaziz University · SADehradun Institute of Technology University · INKing Abdulaziz University · SAQassim University · SATaibah University · SA

Funding

King Khalid University RGP.01-48-42
6 · The paper itself

Abstract

Drug instillation via a topical route is preferred since it is desirable and convenient due to the noninvasive and easy drug access to different segments of the eye for the treatment of ocular ailments. The low dose, rapid onset of action, low or no toxicity to the local tissues, and constrained systemic outreach are more prevalent in this route. The majority of ophthalmic preparations in the market are available as conventional eye drops, which rendered <5% of a drug instilled in the eye. The poor drug availability in ocular tissue may be attributed to the physiological barriers associated with the cornea, conjunctiva, lachrymal drainage, tear turnover, blood-retinal barrier, enzymatic drug degradation, and reflex action, thus impeding deeper drug penetration in the ocular cavity, including the posterior segment. The static barriers in the eye are composed of the sclera, cornea, retina, and blood-retinal barrier, whereas the dynamic barriers, referred to as the conjunctival and choroidal blood flow, tear dilution, and lymphatic clearance, critically impact the bioavailability of drugs. To circumvent such barriers, the rational design of the ocular therapeutic system indeed required enriching the drug holding time and the deeper permeation of the drug, which overall improve the bioavailability of the drug in the ocular tissue. This review provides a brief insight into the structural components of the eye as well as the therapeutic challenges and current developments in the arena of the ocular therapeutic system, based on novel drug delivery systems such as nanomicelles, nanoparticles (NPs), nanosuspensions, liposomes, in situ gel, dendrimers, contact lenses, implants, and microneedles. These nanotechnology platforms generously evolved to overwhelm the troubles associated with the physiological barriers in the ocular route. The controlled-drug-formulation-based strategic approach has considerable potential to enrich drug concentration in a specific area of the eye.

Indexed as

drug deliveryhydrogelimplantmicroneedlenanomicellesnanoparticlesocular therapeutic system

Identifiers

PMID35200463
PMCPMC8871777
OpenAlexW4214690685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.